CA2092711A1 - Compositions and methods for inhibiting growth or replication of viruses - Google Patents

Compositions and methods for inhibiting growth or replication of viruses

Info

Publication number
CA2092711A1
CA2092711A1 CA002092711A CA2092711A CA2092711A1 CA 2092711 A1 CA2092711 A1 CA 2092711A1 CA 002092711 A CA002092711 A CA 002092711A CA 2092711 A CA2092711 A CA 2092711A CA 2092711 A1 CA2092711 A1 CA 2092711A1
Authority
CA
Canada
Prior art keywords
oligonucleotides
oligonucleotide
hybridizable
alkyl
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002092711A
Other languages
English (en)
French (fr)
Inventor
Laure Aurelian
Paul O. P. Ts'o
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of Maryland at Baltimore
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2092711A1 publication Critical patent/CA2092711A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CA002092711A 1990-09-21 1991-09-18 Compositions and methods for inhibiting growth or replication of viruses Abandoned CA2092711A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58618590A 1990-09-21 1990-09-21
US586,185 1990-09-21

Publications (1)

Publication Number Publication Date
CA2092711A1 true CA2092711A1 (en) 1992-03-22

Family

ID=24344663

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002092711A Abandoned CA2092711A1 (en) 1990-09-21 1991-09-18 Compositions and methods for inhibiting growth or replication of viruses

Country Status (8)

Country Link
EP (1) EP0656942A1 (xx)
JP (1) JPH06501162A (xx)
AU (2) AU8756691A (xx)
CA (1) CA2092711A1 (xx)
IE (1) IE913321A1 (xx)
IL (1) IL99543A0 (xx)
NZ (1) NZ239883A (xx)
WO (1) WO1992005284A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8617691A (en) * 1990-08-15 1992-03-17 Genta Incorporated Inhibition of herpesviridae infection by antisense oligonucleotides
WO1994001551A1 (en) * 1992-07-02 1994-01-20 United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of inhibiting viral replication
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
FR2708270B1 (fr) * 1993-07-28 1995-10-20 Genset Sa Oligonucléotides antisens dirigés contre les virus Herpès Simplex de types 1 & 2.
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
AU2604995A (en) * 1994-06-01 1995-12-21 Hybridon, Inc. Branched oligonucleotides as pathogen-inhibitory agents
US7176303B2 (en) 2003-11-06 2007-02-13 Isis Pharmaceuticals, Inc. Modulation of STAT5 expression
WO2024113302A1 (zh) * 2022-12-01 2024-06-06 深圳先进技术研究院 靶向HSV必需基因的gRNA、CRISPR/Cas基因编辑系统、递送系统及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
AU636573B2 (en) * 1988-02-26 1993-05-06 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers

Also Published As

Publication number Publication date
EP0656942A1 (en) 1995-06-14
IL99543A0 (en) 1992-08-18
AU8756691A (en) 1992-04-15
WO1992005284A1 (en) 1992-04-02
NZ239883A (en) 1993-10-26
JPH06501162A (ja) 1994-02-10
EP0656942A4 (xx) 1998-04-15
AU2491095A (en) 1995-11-02
IE913321A1 (en) 1992-02-25

Similar Documents

Publication Publication Date Title
Kulka et al. Site specificity of the inhibitory effects of oligo (nucleoside methylphosphonate) s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4.
Taylor et al. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids
Boldogh et al. Transcriptional activation of cellular oncogenes fos, jun, and myc by human cytomegalovirus
US6265167B1 (en) Targeted RNA degradation using nuclear ribozyme RNA
Zabolotny et al. The herpes simplex virus type 1 2.0-kilobase latency-associated transcript is a stable intron which branches at a guanosine
US5916808A (en) Antisense oligonucleotides which combat aberrant splicing and methods of using the same
US6015886A (en) Oligonucleotide phosphate esters
US5567604A (en) Anti-viral guanosine-rich oligonucleotides
JP5010466B2 (ja) Ｄｎａウイルスのマイクロｒｎａ及びそれを阻害する医薬品
US20040209263A1 (en) Selection of catalytic nucleic acids targeted to infectious agents
AU2003202376A1 (en) Oligonucleotides comprising alternating segments and uses thereof
WO2003064441A2 (en) Oligonucleotides comprising alternating segments and uses thereof
JPH02276577A (ja) ＨＩＶ　Ｉからのトランスアクチベーター標的配列（ＴＡＲ）およびトランスアクチベータータンパク質（Ｔａｔ）の合成の阻害のためのアンチセンスオリゴヌクレオチド類およびそれらの使用
CA2536026A1 (en) Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
AU662040B2 (en) Pseudorabies virus (PRV) polynucleotides and their use for preparing virus-resistant eukaryotic cells
CA2092711A1 (en) Compositions and methods for inhibiting growth or replication of viruses
AU698089B2 (en) Oligonucleotides with anti-cytomegalovirus activity
US5550047A (en) Oligonucleotides with anti-Epstein-Barr virus activity
CA2211877A1 (en) Human immunodeficiency virus transcription inhibitors and methods of their use
US6030830A (en) Immunoglobulin trans-spliced transcripts and uses thereof
Remenick et al. Inhibition of adenovirus DNA replication by vesicular stomatitis virus leader RNA
US20050085435A1 (en) Novel inhibitors of poxvirus replication
Liu et al. Inhibition of the synthesis of proteins needed for Epstein-Barr virus replication by antisense RNA against the zta gene
JPH0977670A (ja) 抗ウイルス剤
JPH0740934B2 (ja) ウイルス増殖阻害方法

Legal Events

Date Code Title Description
FZDE Discontinued